Tilray Medical Reports Positive Results on Cannabis Extract for Chemo-Induced Vomiting

SYDNEY, Australia, Nov. 07, 2024 – Tilray Medical, a division of Tilray Brands, Inc. and a global leader in medical cannabis, recently revealed the results of a significant scientific study titled, "Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)." This study aimed to evaluate the effectiveness of an oral cannabis extract in adults experiencing CINV despite standard treatments.

The trial was randomized and placebo-controlled, involving participants who received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo. These capsules were administered three times daily over a period of six days. The study spanned from 2016 to 2022, including 147 participants in total. The findings indicated that the cannabis extract significantly improved the complete response rate—defined as no vomiting or the need for additional medications—from 8% with placebo to 24% with the THC:CBD combination. Furthermore, the study noted other benefits such as decreased nausea and fewer daily vomiting episodes. However, some side effects were observed, including sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%).

Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, commented on the findings, stating, "These results are promising for cancer patients undergoing chemotherapy. This study is a significant step towards enhancing patient care and quality of life." She also highlighted the company's dedication to advancing medical research, noting that the positive outcomes emphasize the potential benefits of cannabinoids in managing CINV.

Tilray Medical continues its mission to improve lives by providing access to medical cannabis. As a leading provider of EU-GMP-certified medical cannabis products in over 20 countries, the company has actively supported medical trials worldwide, investigating the use of cannabis for various conditions, including pediatric epilepsy, cancer-induced nausea, and PTSD.

Tilray Medical is devoted to transforming lives and promoting dignity for patients in need by ensuring safe and reliable access to a global portfolio of medical cannabis brands such as Tilray, Aphria, Broken Coast, Symbios, and Navcora. From becoming one of the first approved licensed producers of medical cannabis in Canada, Tilray has expanded to build the first GMP-certified cannabis production facilities in Europe, located in Portugal and Germany. Today, Tilray Medical stands as one of the largest suppliers of medical cannabis to patients, healthcare professionals, hospitals, pharmacies, researchers, and governments across 20 countries and five continents.

Tilray Brands, Inc. is a prominent global lifestyle and consumer packaged goods company with a presence in Canada, the United States, Europe, Australia, and Latin America. The company aims to be a leading premium lifestyle entity, offering a diverse range of brands and innovative products that inspire joy and create memorable experiences. Tilray’s extensive platform supports over 40 brands in more than 20 countries, featuring comprehensive cannabis products, hemp-based foods, and craft beverages.

For further details on Tilray Medical, visit their regional websites for Europe, Canada, and Australia-New Zealand. For more information about Tilray Brands and their contributions to enhancing lives through moments of connection, visit Tilray.com and follow @Tilray on social media platforms.